Guangdong VTR Bio-Tech Co Ltd (300381) - Net Assets
Based on the latest financial reports, Guangdong VTR Bio-Tech Co Ltd (300381) has net assets worth CN¥2.61 Billion CNY (≈ $382.29 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.88 Billion ≈ $421.34 Million USD) and total liabilities (CN¥266.84 Million ≈ $39.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300381 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.61 Billion |
| % of Total Assets | 90.73% |
| Annual Growth Rate | 21.51% |
| 5-Year Change | -14.92% |
| 10-Year Change | 26.21% |
| Growth Volatility | 35.09 |
Guangdong VTR Bio-Tech Co Ltd - Net Assets Trend (2007–2025)
This chart illustrates how Guangdong VTR Bio-Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. See Guangdong VTR Bio-Tech Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guangdong VTR Bio-Tech Co Ltd (2007–2025)
The table below shows the annual net assets of Guangdong VTR Bio-Tech Co Ltd from 2007 to 2025. For live valuation and market cap data, see Guangdong VTR Bio-Tech Co Ltd (300381) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.59 Billion ≈ $379.46 Million |
-2.30% |
| 2024-12-31 | CN¥2.65 Billion ≈ $388.39 Million |
-2.96% |
| 2023-12-31 | CN¥2.74 Billion ≈ $400.24 Million |
-2.87% |
| 2022-12-31 | CN¥2.82 Billion ≈ $412.05 Million |
-7.62% |
| 2021-12-31 | CN¥3.05 Billion ≈ $446.02 Million |
-6.59% |
| 2020-12-31 | CN¥3.26 Billion ≈ $477.47 Million |
+19.58% |
| 2019-12-31 | CN¥2.73 Billion ≈ $399.30 Million |
+13.38% |
| 2018-12-31 | CN¥2.41 Billion ≈ $352.18 Million |
+15.14% |
| 2017-12-31 | CN¥2.09 Billion ≈ $305.86 Million |
+1.73% |
| 2016-12-31 | CN¥2.05 Billion ≈ $300.66 Million |
+45.14% |
| 2015-12-31 | CN¥1.42 Billion ≈ $207.15 Million |
+106.54% |
| 2014-12-31 | CN¥685.38 Million ≈ $100.29 Million |
+124.16% |
| 2013-12-31 | CN¥305.76 Million ≈ $44.74 Million |
+25.97% |
| 2012-12-31 | CN¥242.72 Million ≈ $35.52 Million |
+29.11% |
| 2011-12-31 | CN¥188.00 Million ≈ $27.51 Million |
+29.83% |
| 2010-12-31 | CN¥144.81 Million ≈ $21.19 Million |
+16.98% |
| 2009-12-31 | CN¥123.79 Million ≈ $18.11 Million |
+26.17% |
| 2008-12-31 | CN¥98.12 Million ≈ $14.36 Million |
+26.19% |
| 2007-12-31 | CN¥77.75 Million ≈ $11.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong VTR Bio-Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1095.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥434.47 Million | 17.04% |
| Other Components | CN¥2.12 Billion | 82.96% |
| Total Equity | CN¥2.55 Billion | 100.00% |
Guangdong VTR Bio-Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong VTR Bio-Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Hifuture Electric
SHE:002168
|
$423.42 Million |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
$423.54 Million |
|
Thonburi Healthcare Grp Pcl
BK:THG
|
$423.82 Million |
|
InBody Co.Ltd
KQ:041830
|
$423.96 Million |
|
Foseco India Limited
NSE:FOSECOIND
|
$423.21 Million |
|
Jiangnan Yifan Motor Co.Ltd
SHE:301023
|
$423.19 Million |
|
Commercial Bancgroup, Inc. Common Stock
NASDAQ:CBK
|
$423.10 Million |
|
Sunfly Intelligent Technology Co Ltd
SHE:300423
|
$422.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong VTR Bio-Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,611,511,969 to 2,549,472,845, a change of -62,039,124 (-2.4%).
- Net loss of 19,779,508 reduced equity.
- Dividend payments of 49,097,064 reduced retained earnings.
- Other comprehensive income decreased equity by 104,440,113.
- Other factors increased equity by 111,277,561.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-19.78 Million | -0.78% |
| Dividends Paid | CN¥49.10 Million | -1.93% |
| Other Comprehensive Income | CN¥-104.44 Million | -4.1% |
| Other Changes | CN¥111.28 Million | +4.36% |
| Total Change | CN¥- | -2.38% |
Book Value vs Market Value Analysis
This analysis compares Guangdong VTR Bio-Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.52x to 1.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.32 | CN¥5.89 | x |
| 2008-12-31 | CN¥0.40 | CN¥5.89 | x |
| 2009-12-31 | CN¥0.51 | CN¥5.89 | x |
| 2010-12-31 | CN¥0.62 | CN¥5.89 | x |
| 2011-12-31 | CN¥0.80 | CN¥5.89 | x |
| 2012-12-31 | CN¥1.03 | CN¥5.89 | x |
| 2013-12-31 | CN¥1.31 | CN¥5.89 | x |
| 2014-12-31 | CN¥2.44 | CN¥5.89 | x |
| 2015-12-31 | CN¥4.22 | CN¥5.89 | x |
| 2016-12-31 | CN¥4.95 | CN¥5.89 | x |
| 2017-12-31 | CN¥4.77 | CN¥5.89 | x |
| 2018-12-31 | CN¥5.27 | CN¥5.89 | x |
| 2019-12-31 | CN¥5.82 | CN¥5.89 | x |
| 2020-12-31 | CN¥6.36 | CN¥5.89 | x |
| 2021-12-31 | CN¥5.70 | CN¥5.89 | x |
| 2022-12-31 | CN¥5.52 | CN¥5.89 | x |
| 2023-12-31 | CN¥5.33 | CN¥5.89 | x |
| 2024-12-31 | CN¥5.33 | CN¥5.89 | x |
| 2025-12-31 | CN¥5.19 | CN¥5.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong VTR Bio-Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.38%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.15x
- Recent ROE (-0.78%) is below the historical average (9.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 15.46% | 13.43% | 0.69x | 1.67x | CN¥4.06 Million |
| 2008 | 20.77% | 13.25% | 0.86x | 1.82x | CN¥10.12 Million |
| 2009 | 20.53% | 13.61% | 0.92x | 1.63x | CN¥12.56 Million |
| 2010 | 19.55% | 13.00% | 0.95x | 1.59x | CN¥13.77 Million |
| 2011 | 23.05% | 15.96% | 1.04x | 1.38x | CN¥24.44 Million |
| 2012 | 22.61% | 16.22% | 1.14x | 1.22x | CN¥30.51 Million |
| 2013 | 20.69% | 17.58% | 0.95x | 1.23x | CN¥32.62 Million |
| 2014 | 8.31% | 15.32% | 0.37x | 1.45x | CN¥-11.19 Million |
| 2015 | 5.54% | 10.21% | 0.29x | 1.89x | CN¥-57.76 Million |
| 2016 | 5.98% | 7.51% | 0.47x | 1.69x | CN¥-76.39 Million |
| 2017 | 4.15% | 5.36% | 0.39x | 1.98x | CN¥-113.44 Million |
| 2018 | 5.30% | 6.42% | 0.37x | 2.24x | CN¥-100.69 Million |
| 2019 | 5.17% | 6.23% | 0.45x | 1.83x | CN¥-119.00 Million |
| 2020 | 5.43% | 8.45% | 0.41x | 1.57x | CN¥-136.10 Million |
| 2021 | -4.26% | -6.28% | 0.42x | 1.60x | CN¥-398.19 Million |
| 2022 | 0.67% | 1.55% | 0.37x | 1.17x | CN¥-252.36 Million |
| 2023 | -0.41% | -1.35% | 0.26x | 1.18x | CN¥-272.20 Million |
| 2024 | 1.19% | 3.76% | 0.28x | 1.13x | CN¥-230.06 Million |
| 2025 | -0.78% | -2.38% | 0.28x | 1.15x | CN¥-274.73 Million |
Industry Comparison
This section compares Guangdong VTR Bio-Tech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,212,589,599
- Average return on equity (ROE) among peers: 2.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong VTR Bio-Tech Co Ltd (300381) | CN¥2.61 Billion | 15.46% | 0.10x | $423.24 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.64 Billion |
About Guangdong VTR Bio-Tech Co Ltd
Guangdong VTR Bio-Tech Co., Ltd. researches, develops, produces, sells, and services bio-enzyme preparations, biosynthetics, and nutrition and health products in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, plant extracts, pulp and paper, and textile enzymes, as well as biotechnology solutions.… Read more